---
title: "In \"The Big Banks,\" Citigroup is optimistic about the profitability visibility of CDMO companies, with WuXi AppTec, WUXI BIO, and Pharmaron as the top choices"
description: "The Lyon Research Report points out that with the development of AI technology, investors' focus has shifted from AI-enabled industries to AI replacing intermediaries, with a more pronounced positive "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277139282.md"
published_at: "2026-02-27T03:50:24.000Z"
---

# In "The Big Banks," Citigroup is optimistic about the profitability visibility of CDMO companies, with WuXi AppTec, WUXI BIO, and Pharmaron as the top choices

> The Lyon Research Report points out that with the development of AI technology, investors' focus has shifted from AI-enabled industries to AI replacing intermediaries, with a more pronounced positive impact expected on comprehensive Contract Research, Development, and Manufacturing Organizations (CRDMO). Lyon is optimistic about Contract Development and Manufacturing Organizations (CDMO), believing that their profit visibility is superior to that of specialized Contract Research Organizations (CRO). Recommended CDMO stocks include WuXi AppTec, WUXI BIO, and Pharmaron, with target prices of 143.4 yuan, 48.5 yuan, and 28.8 yuan, respectively

Citi published a research report indicating that as AI technology continues to develop, investors' recent focus is shifting from AI-enabled industries to AI replacing intermediaries. For contract research organizations (CROs) and contract manufacturing organizations (CMOs), the positive impact of AI on comprehensive contract research, development, and manufacturing organizations (CRDMOs) is expected to be more evident. In contrast, the accelerated adoption of AI by pharmaceutical companies may have mixed effects on specialized contract research organizations (CROs).

Therefore, Citi is currently more optimistic about contract development and manufacturing organizations (CDMOs), expecting that their better capacity locking ability and longer-term projects will continue to outperform CROs in terms of profit visibility. The global CRO/CDMO sector's top picks remain WuXi AppTec (02359.HK), WuXi Bio (02269.HK), Pharmaron (03759.HK), Lonza Group (LZAGY.US), and Samsung Biologics, all rated "Outperform." The target prices for WuXi AppTec, WuXi Bio, and Pharmaron are set at HKD 143.4, HKD 48.5, and HKD 28.8, respectively

### Related Stocks

- [03759.HK - PHARMARON](https://longbridge.com/en/quote/03759.HK.md)
- [02359.HK - WUXI APPTEC](https://longbridge.com/en/quote/02359.HK.md)
- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [300759.CN - Pharmaron](https://longbridge.com/en/quote/300759.CN.md)
- [603259.CN - WuXi AppTec](https://longbridge.com/en/quote/603259.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Top 5 港股千亿以上公司涨跌幅（2月27日） | 长飞光纤光缆 (06869) 涨 10.06%，成交额 91.0 亿港元，年内累计涨 187.8%。 新鸿基地产 (00016) 涨 7.12%，成交额 23.0 亿港元，年内累计涨 54.2%。 兆易创新 (03986) 跌 7.89%， | [Link](https://longbridge.com/en/news/277164480.md) |
| 早盘趋势｜康龙化成缩量盘整新低可期？消息面驱动或成转折 | 康龙化成（3759.HK）近期表现较为低迷，处于持续缩量盘整态势。日线级别 MACD 仍维持死叉，绿色柱体未见明显收敛，空头氛围浓厚。当前股价窄幅波动在阶段支撑位一线，且多次回踩未见有力买盘介入，显示低位承接意愿有限，而主力资金处于静观其变 | [Link](https://longbridge.com/en/news/271080992.md) |
| 无视海外 “AI 恐慌”，中国市场狂炒 AI 赢家 | 同一个 AI，截然相反的命运。美国市场陷入” 恐慌性抛售”，中国投资者疯狂追捧：智谱 AI 一度暴涨 524%，MiniMax 一度飙升 488%。分歧本质是美国投资者焦虑于丰厚利润池面临竞争威胁，而中国关注的仍是市场渗透。 | [Link](https://longbridge.com/en/news/276531940.md) |
| AI 的未来，马克思已经预言了？ | 当 AI 实现完全自动化，“资本” 将等同于 “劳动力”，劳动价值趋零，传统经济学基础面临崩塌。德银推演两大终局：若 AI 彻底替代人类，财富将高度集中，东西很多却没人买得起，经济走向通缩、低利率、高利润但股市动荡；若 AI 只是赋能工具， | [Link](https://longbridge.com/en/news/277129155.md) |
| 为什么学习 “AI 语言” 可以帮助您的资金经理战胜市场 | 这篇文章讨论了金融专业人士学习 “说 AI” 的重要性，强调掌握 AI 提示技能在行业成功中变得至关重要。AI 工具正在改变工作流程，使分析师和投资组合经理能够提升他们的表现和决策速度。拥抱 AI 提示的公司将获得竞争优势，而抵制的公司可能 | [Link](https://longbridge.com/en/news/276920714.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.